Inhalant abuse with inhalant-induced psychotic disorder with delusions
ICD-10 F18.150 is a billable code used to indicate a diagnosis of inhalant abuse with inhalant-induced psychotic disorder with delusions.
F18.150 refers to a condition characterized by the abuse of inhalants, which are substances that produce chemical vapors that can be inhaled to induce psychoactive effects. This code specifically denotes the presence of inhalant-induced psychotic disorder, which manifests as delusions. Individuals with this disorder may experience significant alterations in perception, thought processes, and behavior due to the toxic effects of inhalants on the central nervous system. Symptoms can include hallucinations, paranoia, and severe mood disturbances. The onset of these symptoms typically occurs during or shortly after inhalant use, and they can persist even after the substance has been cleared from the body. Treatment often involves a combination of detoxification, psychiatric support, and rehabilitation programs aimed at addressing both the substance use disorder and the underlying psychological issues. Effective management requires a multidisciplinary approach, including medical, psychological, and social interventions to support recovery and prevent relapse.
Detailed psychiatric evaluation notes, including history of substance use and mental status examination.
Patients presenting with acute psychosis following inhalant use, requiring hospitalization.
Ensure clear documentation of the timeline of inhalant use and onset of psychotic symptoms.
Comprehensive substance use history and treatment plan, including detoxification protocols.
Patients in outpatient treatment programs for inhalant abuse with concurrent mental health issues.
Document any co-occurring disorders and treatment strategies employed.
Used for follow-up visits for patients with inhalant abuse and psychotic symptoms.
Document the patient's history, mental status, and treatment plan.
Psychiatrists should include detailed notes on the patient's progress and response to treatment.
Symptoms include delusions, hallucinations, paranoia, and significant mood disturbances that arise during or shortly after inhalant use.
